Given the evidence for PRMT5 representing a collateral vulnerability for the MYC-family proteins from our lab and others [5,17] we reasoned that pharmaceutical inhibition of PRMT5 may represent a promising targeted therapy for high-risk neuroblastoma. This evidence concerns the gene MYC and neuroblastoma.